Remove Biopharma Remove Leads Remove Medical science Remove Patients
article thumbnail

7 commercial, sales, and marketing predictions for 2023

pharmaphorum

In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). Rarely are organisations able to view HCP relationships holistically – across clinical, medical, and sales – or reap the benefits of creating a unified understanding of the customer.

article thumbnail

Bringing Therapies from Bench to Bedside: Navigating Challenges in the Last Mile

Clarify Health

The time-consuming and resource-intensive path from the lab bench to the patient bedside starts with drug discovery, progresses to pre-clinical and clinical research, and then enters regulatory review. Any misstep in terms of pricing, reimbursement, or marketing could mean delays in providing therapies to the patients who need them most.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Imagene Profiles Cancer Biomarkers in Real Time

Medgadget

Cancer therapies have proliferated over the past few decades, improving outcomes for many patients. Dean recounted how only two decades ago we only had access to one-size-fits-all treatments that were effective for some patients, but did nothing for others.

article thumbnail

Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

Medgadget

All of these systems operate under the “master-slave” concept, which involves a surgeon sitting behind a console, away from the patient, who manipulates the mechanical arms of the robot via some kind of joystick-like device. More info can be found at the Biomed Israel website.

article thumbnail

Alpha TAU Killing Tumors With Highly Targeted Alpha Radiation

Medgadget

This leads to substantial damage to healthy tissues and too often results in poor outcomes. The rest of the patients had partial responses. with ten patients to try to duplicate the results. which are currently recruiting patients. In Israel, the company already has a ministry of health approval to treat patients.